More recently, the use of the anti-TIGIT blocking antibody tiragolumab, together with PD-1, blocking in colorectal cancer, turned out to be an efficient therapy able to restore the functionality of tumor-infiltrating CD8+ T cells [120]. The gene discussed is TIGIT; the disease is neoplasm.